Up­dat­ed: FDA re­jects Re­gen­eron's bis­pe­cif­ic for lym­phoma over con­fir­ma­to­ry tri­al sta­tus

Re­gen­eron has hit a snag in its at­tempt to bring a new bis­pe­cif­ic an­ti­body to the mar­ket, as the FDA re­ject­ed odronex­tam­ab across two types of blood can­cers.

Ac­cord­ing to the com­pa­ny, the “on­ly ap­prov­abil­i­ty is­sue is re­lat­ed to the en­roll­ment sta­tus of the con­fir­ma­to­ry tri­als,” and the agency didn’t iden­ti­fy any prob­lems with ef­fi­ca­cy, safe­ty, tri­al de­sign, la­bel­ing or man­u­fac­tur­ing in the com­plete re­sponse let­ters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER